OR WAIT null SECS
March 05, 2024
Article
The decision was based on clinical studies demonstrating no clinically meaningful differences between the biosimilar and its reference product.
January 19, 2024
On January 19, 2024, the FDA announced the addition of a Boxed Warning to the labeling of denosumab (Prolia), citing evidence of an increased risk of severe hypocalcemia in patients with chronic kidney disease.
December 19, 2023
Results showed treatment with dipeptidyl peptidase-4 inhibitors (DPP-4i) improved bone mineral density and reduced osteoporosis risk in patients with type 2 diabetes.
July 09, 2023
Patients identified areas of confusion in data presentation and suggested educational support to better engage with the information provided.
June 13, 2023
A prospective, nonrandomized trial has returned results indicating adolescents and young adults who undergo bariatric surgery experienced a decrease in bone density relative to their counterparts who opted for exercise and nutrition counseling.
May 23, 2023
An analysis of data from more than 60,000 postmenopausal women within the Women's Health Initiative has returned results indicating the guideline-recommended FRAX score may be insufficient for making screening decisions.
May 10, 2023
A phase 3 trial comparing QL1206, a denosumab biosimilar, to the reference agent has returned results demonstrating the efficacy, safety, and pharmacokinetic equivalency of the biosimilar to the reference agent.
April 21, 2023
Most associate bariatric surgery with improved health outcomes, but a new study suggests clinicians and patients should be aware of potential changes in bone density brought on as a result of undergoing bariatric surgery.
March 28, 2023
The guidelines were created using a panel of rheumatologists, orthopedic surgeons, and patients.
February 22, 2023
Investigators identify a strong association between exposure to air pollution and bone mineral loss in postmenopausal women.
